UV 1

Drug Profile

UV 1

Alternative Names: UV-1; UV1 synthetic peptide vaccine; UV1 vaccine

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Norwegian Radium Hospital; Ultimovacs AS
  • Developer Oslo University Hospital; Ultimovacs AS
  • Class Cancer vaccines; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant melanoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 12 Sep 2017 Safety and efficacy data from a phase I trial in Malignant melanoma presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 24 Mar 2017 UV 1 is still in phase I/II trials for Malignant melanoma, Non-small cell lung cancer and Prostate cancer in Norway (Intradermal)
  • 01 Nov 2014 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in Norway (Intradermal) (NCT02275416)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top